|1.||Rangaraju, M: 10 articles (04/2006 - 01/2001)|
|2.||Nusrat, Roomi: 9 articles (03/2006 - 05/2004)|
|3.||Leroy, B: 8 articles (04/2005 - 01/2001)|
|4.||Carbon, C: 6 articles (04/2006 - 12/2000)|
|5.||Farrell, David J: 5 articles (03/2009 - 08/2004)|
|6.||Kohno, Shigeru: 5 articles (03/2008 - 04/2003)|
|7.||Tellier, Guy: 5 articles (09/2005 - 08/2003)|
|8.||Zhanel, George G: 4 articles (07/2009 - 01/2002)|
|9.||Brown, Steven D: 4 articles (01/2008 - 04/2004)|
|10.||Tellier, G: 4 articles (04/2006 - 03/2005)|
07/01/2003 - "Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia."
06/01/2003 - "The efficacy of telithromycin has been assessed in six Phase III studies involving adults with mild to moderate community-acquired pneumonia (CAP) with a degree of severity compatible with oral therapy. "
07/01/2006 - "The results support the efficacy of telithromycin in mild to moderate Legionella pneumonia."
07/01/2006 - "We report three cases of Legionella pneumonia, that were improved by early telithromycin therapy. "
07/01/2006 - "However, few reports have indicated the efficacy of telithromycin in community-acquired pneumonia caused by Legionella species. "
|2.||Respiratory Tract Infections (Respiratory Tract Infection)
11/01/2001 - "Telithromycin achieves high and sustained concentrations in ELF and in alveolar macrophages, while it maintains adequate levels in plasma, providing an ideal pharmacokinetic profile for effective treatment of community-acquired respiratory tract infections caused by either common or atypical, including intracellular, respiratory tract pathogens."
09/01/2001 - "Phase III studies have shown telithromycin to be effective in the treatment of community-acquired upper and lower respiratory tract infections. "
01/01/2005 - "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections. "
10/01/2004 - "Telithromycin is an effective first-line treatment for mild to moderate respiratory infections in adults."
04/01/2005 - "Telithromycin is a new ketolide antimicrobial, that can be useful for the treatment of respiratory infections. "
06/01/2003 - "Telithromycin was also highly effective in patients with infections caused by atypical and/or intracellular pathogens and those at increased risk of morbidity. "
03/01/2004 - "Telithromycin cured the infection in 74% of the young and 67% of the old mice but this difference was not significant. "
12/01/2003 - "To estimate the potential efficacy of telithromycin in the treatment of gynecological infections, a pharmacokinetic study was conducted in 13 Japanese subjects. "
06/01/2004 - "The efficacy of telithromycin, a new ketolide antibiotic, was investigated in the treatment of acute Chlamydia pneumoniae infection in a mouse model. "
01/01/2007 - "However, there have been no studies on the effects of telithromycin (TEL) on chronic respiratory infection in vivo. "
03/01/2005 - "Telithromycin for the treatment of acute exacerbations of chronic bronchitis."
01/01/2005 - "Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis."
06/01/2005 - "Telithromycin, available in an oral formulation, is approved by the US Food and Drug Administration for use in adults for treatment of (1) community-acquired pneumonia due to Streptococcus pneumoniae (including multidrug-resistant isolates), Haemophilus influenzae, Moraxella catarrhalis, Chlamydia pneumoniae, or Mycoplasma pneumoniae; (2) acute exacerbation of chronic bronchitis due to S. "
10/01/2005 - "Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization."
10/01/2005 - "To demonstrate equivalence in the clinical efficacy of telithromycin vs clarithromycin treatment of outpatients with acute exacerbations of chronic bronchitis (AECB), and to compare the tolerability and respiratory-related health-care resource utilization associated with these treatment regimens. "
03/01/2005 - "In a pooled analysis of three large controlled clinical trials involving patients with acute maxillary sinusitis, the bacteriological efficacy of 5- or 10-day treatment with telithromycin and 10-day treatment with comparators was evaluated. "
04/01/2005 - "Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis."
03/01/2005 - "Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis."
04/01/2005 - "The aim of this study was to evaluate the efficacy and tolerance of 5 days of telithromycin (800 mg once a day) in the treatment of bacteriologically proven acute maxillary sinusitis (AMS). "
09/01/2005 - "Telithromycin for the treatment of acute bacterial maxillary sinusitis: a review of a new antibacterial agent."
|9.||Clavulanic Acid (Potassium Clavulanate)
|10.||cefuroxime axetil (Ceftin)
|2.||Transplantation (Transplant Recipients)